PRECISION.
RESEARCH.

Clinical development has progressed through Phase 3. A published Phase 2 randomized trial enrolled adults with obesity or overweight plus a weight-related condition.

Triple receptor agonist: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors.

Human randomized clinical-trial evidence exists, but the product remains investigational pending regulatory review.

Not FDA-approved. Retatrutide remains investigational.

The literature is dominated by animal and laboratory studies. Human evidence remains limited.

Proposed pathways in preclinical research include nitric-oxide signaling, angiogenesis-related pathways, growth-factor signaling and inflammatory mediators.

Preclinical evidence is extensive relative to human evidence. Human safety and efficacy remain insufficiently characterized.

Not FDA-approved for human therapeutic use.

Research on thymosin beta-4 and related fragments includes cell migration, actin biology, angiogenesis and tissue-response models.

Thymosin beta-4 biology is associated with actin binding and cellular migration.

Mostly preclinical or extrapolated from thymosin beta-4 literature; robust controlled human evidence for commercial TB-500 products is lacking.

TB-500 is not an FDA-approved therapeutic drug.

Glutathione is widely studied in oxidative stress, detoxification reactions, thiol homeostasis, immune biology and mitochondrial function.

The reduced/oxidized glutathione couple participates in redox reactions. GSH also acts as a substrate or cofactor in enzymatic antioxidant systems.

Glutathione biology is well established. Clinical effects depend heavily on indication, formulation and route.

Regulatory status varies by formulation and intended use.

Preclinical studies have examined KPV and related melanocortin-derived peptides in inflammatory skin, gastrointestinal, ocular and other experimental models.

Reported experimental effects include modulation of inflammatory signaling, cytokine activity and immune-cell responses.

Evidence is largely preclinical and mechanistic. Controlled clinical evidence is limited.

KPV is not FDA-approved as a therapeutic drug.

It has been studied as a GHRH receptor agonist and historically had FDA-approved Geref products.

GHRH receptor agonism stimulates signaling in pituitary somatotroph cells and can promote endogenous growth-hormone release in appropriate clinical contexts.

Historical clinical and regulatory evidence exists for Geref, but that evidence does not automatically establish equivalence of current compounded or research products.

Historical Geref NDAs were FDA approved and later discontinued.

Published literature discusses collagen and glycosaminoglycan synthesis, tissue-remodeling pathways, cell signaling and topical cosmetic applications.

GHK binds copper(II). Proposed biological actions include modulation of extracellular-matrix and repair-related pathways.

There is substantial laboratory and cosmetic interest, but evidence varies by model and formulation.

GHK-Cu is not FDA-approved as an injectable therapeutic drug.

It is used as a diluent in labeled drug products when the drug's instructions specifically call for it.

Not a therapeutic peptide. It functions as a diluent/vehicle rather than an active pharmacologic ingredient.

FDA-approved bacteriostatic water products have manufacturer-specific labeling, preservative concentration, container size and use instructions.

Regulatory status belongs to the exact manufactured product.